Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug

Posted
Asahi Kasei’s Hovilpri is now approved for treating lesions caused by herpes simplex virus infection. This daily pill came from the $919 million acquisition of AiCuris Anti-Infective Cures. The post Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug appeared first on MedCity News.

Continue reading at MedCity News »

BioPharma, Legal, Pharma, antiviral, Asahi Kasei, biopharma nl, Clinical Trials, FDA, herpes, Herpes Simplex Virus, Japan